NinePointTwo Capital’s Bionano Genomics BNGO Stock Holding History

NinePointTwo Capital’s Portfolio BNGO Stock Details BNGO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-47	Closed	-$84K	–	230
2021 Q4	$84K	Buy	+47	New	+$126K	0.03%	184

Other funds holding BNGO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank Julius Baer & Co Zurich, Switzerland $33.2B AUM 25.01% 1-Year Est. Return

Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

Mitsubishi UFJ Asset Management Tokyo, Japan $149B AUM 24.71% 1-Year Est. Return

NinePointTwo Capital's BNGO Position: Q1 2022 in Review

NinePointTwo Capital sold out of Bionano Genomics (BNGO) in Q1 2022, closing a stake of 47 shares — an estimated $84K sold.

NinePointTwo Capital first reported a position in BNGO in Q4 2021 and held it in 1 quarter. The position peaked at $84K in Q4 2021. 148 funds tracked by Wall St. Rank hold BNGO as of Q1 2022.

NinePointTwo Capital reported no remaining Bionano Genomics position as of Q1 2022 after selling out during the quarter.
NinePointTwo Capital sold 47 Bionano Genomics shares in Q1 2022, an estimated $84K.
NinePointTwo Capital first reported a position in Bionano Genomics in Q4 2021 and held it in 1 quarter.
NinePointTwo Capital's Bionano Genomics position peaked at $84K in Q4 2021.
148 funds tracked by Wall St. Rank held Bionano Genomics as of Q1 2022.

Based on NinePointTwo Capital's 13F filing for Q1 2022, filed 16 May 2022.